NO20076420L - Anvendelse av thiazolderivater og analoger i behandling av sykdommer forarsaket av frie fettsyrer - Google Patents

Anvendelse av thiazolderivater og analoger i behandling av sykdommer forarsaket av frie fettsyrer

Info

Publication number
NO20076420L
NO20076420L NO20076420A NO20076420A NO20076420L NO 20076420 L NO20076420 L NO 20076420L NO 20076420 A NO20076420 A NO 20076420A NO 20076420 A NO20076420 A NO 20076420A NO 20076420 L NO20076420 L NO 20076420L
Authority
NO
Norway
Prior art keywords
treatment
fatty acids
free fatty
analogues
diseases caused
Prior art date
Application number
NO20076420A
Other languages
English (en)
Inventor
Jacob Westman
Guido Kurz
Bjorn Eriksson
Christian Hedberg
Original Assignee
Betagenon Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Ab filed Critical Betagenon Ab
Publication of NO20076420L publication Critical patent/NO20076420L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anvendelse av en forbindelse med formelen (I), der X, T, Y5, W, A1, R1, R5 og R6 har betydning som angitt i beskrivelsen, i framstilling av et medikament for behandling av en lidelse forårsaket av, forbundet med, eller bidratt til, av frie fettsyrer, slik som hyperinsulinemi og relaterte lidelser, inkludert type 2 diabetes og tilsvarende.
NO20076420A 2005-07-21 2007-12-13 Anvendelse av thiazolderivater og analoger i behandling av sykdommer forarsaket av frie fettsyrer NO20076420L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59562005P 2005-07-21 2005-07-21
SE0501721 2005-07-21
US74442206P 2006-04-07 2006-04-07
PCT/GB2006/002743 WO2007010281A2 (en) 2005-07-21 2006-07-21 Use of thiazole derivatives and analogues in disorders caused by free fatty acids

Publications (1)

Publication Number Publication Date
NO20076420L true NO20076420L (no) 2008-04-09

Family

ID=37669179

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20076333A NO20076333L (no) 2005-07-21 2007-12-11 Anvendelse av thiazolderivater og analoge i behandling av kreft
NO20076420A NO20076420L (no) 2005-07-21 2007-12-13 Anvendelse av thiazolderivater og analoger i behandling av sykdommer forarsaket av frie fettsyrer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20076333A NO20076333L (no) 2005-07-21 2007-12-11 Anvendelse av thiazolderivater og analoge i behandling av kreft

Country Status (10)

Country Link
US (2) US20090156644A1 (no)
EP (2) EP1906955A2 (no)
JP (2) JP2009501776A (no)
KR (2) KR20080034436A (no)
AU (2) AU2006271375A1 (no)
CA (2) CA2615752A1 (no)
EA (2) EA200800303A1 (no)
IL (2) IL188031A0 (no)
NO (2) NO20076333L (no)
WO (2) WO2007010273A2 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005024012A1 (de) * 2005-05-20 2006-11-23 Grünenthal GmbH Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
WO2008090327A1 (en) * 2007-01-22 2008-07-31 Betagenon Ab New combination for use in the treatment of cancer
CN101674833A (zh) * 2007-03-20 2010-03-17 柯瑞斯公司 含有锌结合半族的Raf激酶抑制剂
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
WO2009019446A1 (en) * 2007-08-03 2009-02-12 Betagenon Ab Compounds useful as medicaments
BRPI0818658A2 (pt) 2007-10-09 2015-04-14 Merck Patent Ges Mit Beschränkter Haftung Derivados de piridina úteis como ativadores de glicoquinase
EP2217235A4 (en) * 2007-11-15 2011-01-12 Musc Found For Res Dev INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
KR100998572B1 (ko) * 2007-12-14 2010-12-07 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는 페닐아미노티아졸론유도체 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 암 예방 및 치료용 조성물
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
JP5982281B2 (ja) 2009-07-08 2016-08-31 バルティック バイオ アーベー 医薬として有用な化合物
US9221773B2 (en) * 2009-12-22 2015-12-29 The Translational Genomics Research Institute Benzamide derivatives
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
EP2760856B1 (en) * 2011-09-30 2016-09-14 Bristol-Myers Squibb Company Selective nr2b antagonists
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
CN104059060B (zh) * 2014-05-30 2017-08-01 西安交通大学 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
JP2022544389A (ja) * 2019-08-15 2022-10-18 バイエル・アクチエンゲゼルシヤフト ２－（フェニルイミノ）－３－アルキル－１，３－チアゾリジン－４－オンの製造方法
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345374A (en) * 1962-09-04 1967-10-03 Bayer Ag Certain oxathiazole and dithiazole derivatives
US3671537A (en) * 1969-06-05 1972-06-20 Gyogyszerkutato Intezet Certain 3-(2,6-dichlorophenyl)-2-iminothiazolidines
US4103018A (en) * 1976-10-12 1978-07-25 Schering Corporation 2-[4-(Polyhalo-2-hydroxy-2-propyl)anilino]-2-oxazolin-4-ones and thiazolin-4-ones corresponding thereto
HU191408B (en) * 1984-04-25 1987-02-27 Egis Gyogyszergyar,Hu Process for preparing new imino-thiazolidine derivatives
DD246541A1 (de) * 1986-01-27 1987-06-10 Univ Halle Wittenberg Verfahren zur herstellung von 5-arylidenthiazolidin-4-onen
DD270072A1 (de) * 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US6353006B1 (en) * 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
US20040152667A1 (en) * 2002-10-23 2004-08-05 Hauske James R. 4-Alkenylthiazoles comprising epoxide functionality, and methods of use thereof
WO2005082363A1 (en) * 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer
CA2564751A1 (en) * 2004-04-30 2005-11-24 Schering Corporation Neuropeptide receptor modulators
MXPA06015028A (es) * 2004-07-01 2007-02-08 Hoffmann La Roche Tiazolinas cinolinas no sustituidas.
MX2007001539A (es) * 2004-08-10 2007-04-23 Exelisis Inc Compuestos heterociclicos como agentes farmaceuticos.
CN101039939B (zh) * 2004-10-14 2010-07-07 霍夫曼-拉罗奇有限公司 作为cdk1抑制剂的喹唑啉基亚甲基噻唑啉酮类
CN100525929C (zh) * 2005-04-20 2009-08-12 郭文礼 喷水枪出水控制装置
WO2007005785A1 (en) * 2005-07-04 2007-01-11 Dr. Reddy's Laboratories Ltd. Thiazoles derivatives as ampk activator

Also Published As

Publication number Publication date
US20090156644A1 (en) 2009-06-18
JP2009501775A (ja) 2009-01-22
KR20080034436A (ko) 2008-04-21
KR20080032096A (ko) 2008-04-14
WO2007010281A2 (en) 2007-01-25
WO2007010281A3 (en) 2007-06-07
AU2006271375A2 (en) 2007-01-25
NO20076333L (no) 2008-04-01
CA2614327A1 (en) 2007-01-25
IL188163A0 (en) 2008-03-20
EA200800303A1 (ru) 2008-10-30
WO2007010273A3 (en) 2007-05-10
AU2006271375A1 (en) 2007-01-25
CA2615752A1 (en) 2007-01-25
EP1906956A2 (en) 2008-04-09
EA200800302A1 (ru) 2008-08-29
WO2007010273A2 (en) 2007-01-25
AU2006271383A1 (en) 2007-01-25
JP2009501776A (ja) 2009-01-22
EP1906955A2 (en) 2008-04-09
US20090136472A1 (en) 2009-05-28
IL188031A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
NO20076420L (no) Anvendelse av thiazolderivater og analoger i behandling av sykdommer forarsaket av frie fettsyrer
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
NO20082096L (no) Azaindol-2-karboksamidderivativer
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
MA32175B1 (fr) Oxadiazoanthracènes pour le traitement du diabète
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
NO20090590L (no) Metabolisme modulatorer samt behandling av lidelser relatert dertil
BRPI0716598A2 (pt) Derivados de (hetero) arilsulfonamida de n-biarila úteis no tratamento de doenças medidas por interações de linfócitos
NO20090591L (no) Metabolisme modulatorer samt behandling av lidelser relatert dertil
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
MY174002A (en) Combination theraphy for the treatment of diabetes
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
NO20054408L (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
UY28006A1 (es) Agonistas ppar quirales
PH12013500711A1 (en) Acylbenzene derivative
EA200970970A1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидо-4-пиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения моторных нарушений, связанных с болезнью паркинсона
MX2014000929A (es) Derivados de amida sustituidos con n-hetero-anillo.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application